ONCOLOGICAL CARE FOR THE PATIENTS WITH HEPATOCELLULAR CARCINOMA IN SVERDLOVSK REGION
Vol. 66 No. 4 (2020), STATISTICS
Vol. 66 No. 4 (2020)

ONCOLOGICAL CARE FOR THE PATIENTS WITH HEPATOCELLULAR CARCINOMA IN SVERDLOVSK REGION

STATISTICS
https://doi.org/10.37469/0507-3758-2020-66-4-364-369
Published 01.04.2020
Vladislav Petkau
Federal State Budget Educational Institution of Higher Education «Ural State Medical University», State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Clinical Hospital»
V. Breder
Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation
E. Bessonova
Federal State Budget Educational Institution of Higher Education «Ural State Medical University», State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Clinical Hospital»
A. Tarkhanov
State Autonomous Healthcare Institution of the Sverdlovsk Region «Sverdlovsk Regional Oncological Dispensary»
PDF (Русский)

Keywords

HEPATOCELLULAR CARCINOMA (HCC)
LIVER CANCER
EPIDEMIOLOGY
RISK FACTORS
MULTIDISCIPLINARY TEAM

How to Cite

Petkau, V., Breder, V., Bessonova, E., & Tarkhanov, A. (2020). ONCOLOGICAL CARE FOR THE PATIENTS WITH HEPATOCELLULAR CARCINOMA IN SVERDLOVSK REGION. Voprosy Onkologii, 66(4), 364–369. https://doi.org/10.37469/0507-3758-2020-66-4-364-369
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

HCC epidemiologic data in Sverdlovsk region are presented in current issue. 1293 of new cases of HCC were diagnosed since 2015 till 2019. The incidence rate of HCC in 2019 was 6,53 cases per 100000 people and standardized incidence ratio was 3,48 per 100000 people. The maximum of new cases was among the people older than 70 years. HCC developed in cirrhotic liver in 70,2% of cases. The main risk factors were virus hepatitis (49,6%), regular alcohol consumption (23%) and obesity (9,9%). The post-mortem diagnosis exceeds 40% of cases. The one-year mortality was 72-73%. The number of patients with HCC sent to the regional oncology dispensary increased in the last 5 years in 5 times. There were 124 of such patients in 2019. The majority has HCC at BCLC D stage (56,5%). Only 16,7% of patients received specialized treatment. The introduction of multidisciplinary team led to a doubling of annual number of treated patients with HCC.
https://doi.org/10.37469/0507-3758-2020-66-4-364-369
PDF (Русский)

References

1. Bray F, Colombet M., Mery L. et al. Cancer Incidence in Five Continents, Vol. XI (electronic version). - Lyon: International Agency for Research on Cancer, 2020.

2. Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA Cancer J Clin. - 2018. - Vol. 68(6). - P. 394-424. - DOI: 10.3322/caac.21492

3. Singal A.G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends // J. Hepatol. - 2020. - Vol. 72(2). - P. 250-261. - DOI: 10.1016/j.jhep.2019.08.025

4. Каприн А.Д., Старинский В.В., Петрова ГВ. Состояние онкологической помощи населению России в 2018 году. - М.: МНИОИ им. П.А. Герцена филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2019. - илл. - 236 с.

5. Petrick J.L., Kelly S.P., Altekruse S.F et al. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030 // J Clin Oncol. - Vol. 34. - P. 1787-1794. - DOI: 10.1200/JCO.2015.64.7412

6. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). - М.: МНИОИ им. П.А. Герцена филиал ФГБУ "НМИРЦ" Минздрава России, 2019. - 250 с.

7. Мерабишвили В.М., Мерабишвили Э.Н., Чепик О.Ф. Эпидемиология рака печени. Заболеваемость, смертность, динамика гистологической структуры // Сибирский онкологический журнал. - 2015. - № 2. - С. 5-14.

8. Breder V.V., Patutko Y.I., Peregudova M.V. et al. Comparative analysis of the modern staging systems of hepatocellular carcinoma - TNM/AJCC, CUPI, CLIP and BCLC from everyday clinical practice in Russia. The experience of Russian Oncological Scientific Center n. a. NN Blokhin // Malignant Tumours. - 2016. - Vol. 2. - P. 28-36. - DOI: 10.18027/2224-5057-2016-2-28-36

9. Бредер В. В., Балахнин П. В., Виршке Э. Р. и др. Практические рекомендации по лекарственному лечению гепатоцеллюлярного рака // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. - 2019. - Т. 9. - С. 420-438. - DOI: 10.18027/2224-5057-2019-9-3s2-420-438

10. Llovet J.M., Br C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification // Semin Liver Dis. - 1999. - Vol. 19. - P. 329-338. - 10.1055/ s-2007-1007122. DOI: 10.1055/s-2007-1007122

11. Чекмазов И.А., Иваников И.О., Сапронов Г.В. и др. Рак печени: этиология, патогенез, итоги длительного клинико-эпидемиологического наблюдения // Доказательная гастроэнтерология. - 2019. - Vol. 8(1). - P. 5-15. - DOI: 10.17116/dokgastro201980115

12. Бредер В.В., Виршке Э.Р., Кудашкин Н.Е. и др. Факторы прогноза выживаемости больных гепатоцеллюлярным раком в российской популяции пациентов. Опыт Российского онкологического научного центра имени Н.Н.Блохина // Вестник ФГБУ "РОНЦ им. Н.Н. Блохина". - 2016. - Т. 27. - № 2. - С.72-85.

13. Park J.W., Chen M., Colombo M. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study // Liver International. - 2015. - Vol. 35(9). - P. 2155-2166.

14. Johnson P., Berhane S., Kagebayashi C. et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance // British Journal of Cancer. - 2017. - Vol. 116. - P. 441-447. - DOI: 10.1038/bjc.2016.422

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2020

Most read articles by the same author(s)